Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0DFNXA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2023173026A1 ADC-L078-045
|
|||||
| Synonyms |
ADC-L078-045
Click to Show/Hide
|
|||||
| Organization |
VIVASOR, INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.8-4.1
|
|||||
| Structure |
|
|||||
| Antibody Name |
undisclosed
|
|||||
| Antigen Name |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
|
Antigen Info | ||||
| Payload Name |
L078-043 payload
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
Mal-PEG4-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
WO2023173026A1-ADC-L078-045-Linker-L078-043
|
|||||